뉴스벤징가
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
· 발표
기사 요약
Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…